文献速递淋巴瘤

CD19 CAR-T细胞产品类型对复发或难治性侵袭性B细胞非霍奇金淋巴瘤结局的影响

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
PubMed 文献 · Blood · 2022-01-01

该回顾性研究分析了129例接受环磷酰胺和氟达拉滨淋巴清除后输注CD19 CAR-T细胞(阿基仑赛、替沙仑赛或研究性产品JCAR014)的复发或难治性侵袭性B细胞非霍奇金淋巴瘤患者,经多因素校正后,CAR-T产品类型仍独立影响毒性及疗效,JCAR014和替沙仑赛的细胞因子释放综合征及神经毒性严重程度低于阿基仑赛,但完全缓解率低于阿基仑赛。

要点

  • JCAR014独立与较低的细胞因子释放综合征严重程度相关(aOR 0.19,95%CI 0.08-0.46)。
  • 替沙仑赛和JCAR014均与较低的免疫效应细胞相关神经毒性综合征严重程度相关(aOR 0.17)。
  • 替沙仑赛和JCAR014相比阿基仑赛完全缓解率更低。

核心结论

  • CD19 CAR-T细胞产品类型独立影响复发或难治性侵袭性B细胞非霍奇金淋巴瘤患者的毒性和疗效。

研究设计与样本

  • 回顾性分析129例接受环磷酰胺和氟达拉滨淋巴清除后输注CD19 CAR-T细胞(阿基仑赛、替沙仑赛或研究性产品JCAR014)的复发或难治性侵袭性B细胞非霍奇金淋巴瘤患者。
  • JCAR014来自1/2期临床试验(NCT01865617)。

主要发现

  • 经年龄、造血细胞移植特异性合并症指数、乳酸脱氢酶、最大病灶直径和绝对淋巴细胞计数校正后,CAR-T产品类型仍与结局相关。
  • JCAR014相比阿基仑赛独立与较低的细胞因子释放综合征严重程度相关(aOR 0.19,95%CI 0.08-0.46)。
  • 替沙仑赛相比阿基仑赛有较低的细胞因子释放综合征严重程度趋势(aOR 0.47,95%CI 0.21-1.06;P=0.07)。
  • 替沙仑赛(aOR 0.17,95%CI 0.06-0.48)和JCAR014(aOR 0.17,95%CI 0.06-0.47)相比阿基仑赛均与较低的免疫效应细胞相关神经毒性综合征严重程度相关。
  • 相比阿基仑赛,替沙仑赛和JCAR014预测完全缓解的比值更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T cells are novel therapies showing great promise for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL). Single-arm studies showed significant variations in outcomes across distinct CD19 CAR T-cell products. To estimate the independent impact of the CAR T-cell product type on outcomes, we retrospectively analyzed data from 129 patients with R/R aggressive B-NHL treated with cyclophosphamide and fludarabine lymphodepletion followed by either a commercially available CD19 CAR T-cell therapy (axicabtagene ciloleucel [axicel] or tisagenlecleucel [tisacel]), or the investigational product JCAR014 on a phase 1/2 clinical trial (NCT01865617). After adjustment for age, hematopoietic cell transplantation-specific comorbidity index, lactate dehydrogenase (LDH), largest lesion diameter, and absolute lymphocyte count (ALC), CAR T-cell product type remained associated with outcomes in multivariable models. JCAR014 was independently associated with lower cytokine release syndrome (CRS) severity compared with axicel (adjusted odds ratio [aOR], 0.19; 95% confidence interval [CI]; 0.08-0.46), with a trend toward lower CRS severity with tisacel compared with axicel (aOR, 0.47; 95% CI, 0.21-1.06; P = .07). Tisacel (aOR, 0.17; 95% CI, 0.06-0.48) and JCAR014 (aOR, 0.17; 95% CI, 0.06-0.47) were both associated with lower immune effector cell-associated neurotoxicity syndrome severity compared with axicel. Lower odds of complete response (CR) were predicted with tisacel and JCAR014 compared with axicel. Although sensitivity analyses using either positron emission tomography- or computed tomography-based response criteria also suggested higher efficacy of axicel over JCAR014, the impact of tisacel vs axicel became undetermined. Higher preleukapheresis LDH, largest lesion diameter, and lower ALC were independently associated with lower odds of CR. We conclude that CD19 CAR T-cell product type independently impacts toxicity and efficacy in R/R aggressive B-NHL patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gauthier J, Gazeau N, Hirayama AV, et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood. 2022. PMID: 35439295. doi:10.1182/blood.2021014497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。